Nasdaq
$0.7448▲ 0.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $252.1MShares out 3.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.15Pre-market26.10.15 21:018-KKey event#●●●#●●●
Ocugen, Inc.
Ocugen released an investor presentation on October 15, 2026, detailing the clinical progress of its retinal disease pipeline and the approval of its OCU400 Early Access Program (EAP) in the Bahamas. The company targets topline data for OCU400 in 1H 2027 followed by a BLA submission in 2Q 2027, with OCU410ST and OCU410 also advancing toward data readouts and BLA filings in 2027 and 2028, respectively.…more
$0.7448+0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15Pre-market26.10.15 10:22filed8-KKey event
Ocugen, Inc.
Ocugen has entered into an exclusive license and supply agreement with Roots Pharmaceutical for its retinitis pigmentosa gene therapy, OCU400, covering the Middle East and North Africa. Under the deal, Ocugen is set to receive up to $4 million in upfront and development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Additionally, the company has postponed its special meeting of stockholders regarding a proposal to increase authorized common shares to December 22, 2026.…more
$0.7448+0.88%vs prev closeView filingShare - 10.14Overnight26.10.14 10:074Ownership
Ocugen, Inc.
Ocugen, Inc. CEO Musunuri Shankar reported an insider transaction of company shares on October 9, 2026. This filing serves as an official disclosure of executive equity changes to the SEC.…more
$0.7448+0.88%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 20:00#●●●#●●●
Ocugen to Report Q3 2026 Financial Results on November 4
Ocugen will host a conference call on November 4, 2026, to discuss its third-quarter financial results and provide a business update. This announcement is a routine disclosure of the earnings schedule.…more
$0.7448+0.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Pre-market26.10.14 19:30
●●●●●●●● ●●●●● ●●●●●●
Ocugen has entered into an exclusive licensing agreement with Roots Pharmaceutical to bring its OCU400 gene therapy for retinitis pigmentosa to the Middle East and North Africa. The deal includes up to $4 million in upfront and development payments, along with potential sales milestones and royalties.…more
$0.7448+0.88%vs prev close - 10.6Pre-market26.10.06 20:02
●●●●●●●● ●●●●● ●●●●●●
Ocugen has established a new European affiliate in Amsterdam and appointed Jolanda Crombach as General Manager to lead its regional operations. This move is intended to support upcoming regulatory submissions and the potential commercialization of its Phase 3 gene therapy programs in Europe.…more
$0.7448+0.88%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report